BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

456 related articles for article (PubMed ID: 30741768)

  • 21. Long-Term Outcome of Rectal Cancer With Clinically (EUS/MRI) Metastatic Mesorectal Lymph Nodes Treated by Neoadjuvant Chemoradiation: Role of Organ Preservation Strategies in Relation to Pathologic Response.
    Belluco C; Forlin M; Olivieri M; Cannizzaro R; Canzonieri V; Buonadonna A; Bidoli E; Matrone F; Bertola G; De Paoli A
    Ann Surg Oncol; 2016 Dec; 23(13):4302-4309. PubMed ID: 27489059
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oncologic outcomes after neoadjuvant chemoradiation followed by curative resection with tumor-specific mesorectal excision for fixed locally advanced rectal cancer: Impact of postirradiated pathologic downstaging on local recurrence and survival.
    Kim NK; Baik SH; Seong JS; Kim H; Roh JK; Lee KY; Sohn SK; Cho CH
    Ann Surg; 2006 Dec; 244(6):1024-30. PubMed ID: 17122629
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Short-term preoperative radiotherapy is a safe approach for treatment of locally advanced rectal cancer.
    Korkolis DP; Plataniotis GD; Gondikakis E; Xinopoulos D; Koulaxouzidis GV; Katsilieris J; Vassilopoulos PP
    Int J Colorectal Dis; 2006 Jan; 21(1):1-6. PubMed ID: 15947936
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lymph Node Yield After Neoadjuvant Chemoradiotherapy in Rectal Cancer Specimens: A Randomized Trial Comparing Two Fixatives.
    Dias AR; Pereira MA; de Mello ES; Nahas SC; Cecconello I; Ribeiro U
    Dis Colon Rectum; 2018 Aug; 61(8):888-896. PubMed ID: 29944580
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictive factors of tumor response after neoadjuvant chemoradiation for locally advanced rectal cancer.
    Moureau-Zabotto L; Farnault B; de Chaisemartin C; Esterni B; Lelong B; Viret F; Giovannini M; Monges G; Delpero JR; Bories E; Turrini O; Viens P; Salem N
    Int J Radiat Oncol Biol Phys; 2011 Jun; 80(2):483-91. PubMed ID: 21093174
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pathologic complete response implies a fewer number of lymph nodes in specimen of rectal cancer patients treated by neoadjuvant therapy and total mesorectal excision.
    Bustamante-Lopez LA; Nahas CSR; Nahas SC; Marques CFS; Pinto RA; Cotti GC; Imperiale AR; de Mello ES; Ribeiro U; Cecconello I
    Int J Surg; 2018 Aug; 56():283-287. PubMed ID: 29981939
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A systematic review comparing radiation toxicity after various endorectal techniques.
    Verrijssen AS; Opbroek T; Bellezzo M; Fonseca GP; Verhaegen F; Gerard JP; Sun Myint A; Van Limbergen EJ; Berbee M
    Brachytherapy; 2019; 18(1):71-86.e5. PubMed ID: 30396854
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neoadjuvant chemoradiotherapy with radiation dose escalation with contact x-ray brachytherapy boost or external beam radiotherapy boost for organ preservation in early cT2-cT3 rectal adenocarcinoma (OPERA): a phase 3, randomised controlled trial.
    Gerard JP; Barbet N; Schiappa R; Magné N; Martel I; Mineur L; Deberne M; Zilli T; Dhadda A; Myint AS;
    Lancet Gastroenterol Hepatol; 2023 Apr; 8(4):356-367. PubMed ID: 36801007
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transanal endoscopic microsurgery for residual rectal cancer (ypT0-2) following neoadjuvant chemoradiation therapy: another word of caution.
    Perez RO; Habr-Gama A; Lynn PB; São Julião GP; Bianchi R; Proscurshim I; Gama-Rodrigues J
    Dis Colon Rectum; 2013 Jan; 56(1):6-13. PubMed ID: 23222274
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of pathological complete response rates after neoadjuvant short-course radiotherapy or chemoradiation followed by delayed surgery in locally advanced rectal cancer.
    Hoendervangers S; Couwenberg AM; Intven MPW; van Grevenstein WMU; Verkooijen HM
    Eur J Surg Oncol; 2018 Jul; 44(7):1013-1017. PubMed ID: 29650419
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nodal Disease in Rectal Cancer Patients With Complete Tumor Response After Neoadjuvant Chemoradiation: Danger Below Calm Waters.
    Baucom RB; Maguire LH; Kavalukas SL; Geiger TM; Ford MM; Muldoon RL; Hopkins MB; Hawkins AT
    Dis Colon Rectum; 2017 Dec; 60(12):1260-1266. PubMed ID: 29112561
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Histologic response after neoadjuvant therapy in rectal adenocarcinoma: own experience and review of the literature].
    Mátrai Z; Lövey J; Hitre E; Orosz Z; Gödény M; Péley G; Sulyok Z; Rényi Vámos F; Farkas E; Köves I
    Orv Hetil; 2006 Oct; 147(42):2011-20. PubMed ID: 17165600
    [TBL] [Abstract][Full Text] [Related]  

  • 33. T-level downstaging and complete pathologic response after preoperative chemoradiation for advanced rectal cancer result in decreased recurrence and improved disease-free survival.
    Theodoropoulos G; Wise WE; Padmanabhan A; Kerner BA; Taylor CW; Aguilar PS; Khanduja KS
    Dis Colon Rectum; 2002 Jul; 45(7):895-903. PubMed ID: 12130878
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Preoperative diagnostic procedures in locally advanced rectal carcinoma (> or =T3 or N+). What does endoluminal ultrasound achieve at staging and restaging (after neoadjuvant radiochemotherapy) in contrast to computed tomography?].
    Liersch T; Langer C; Jakob C; Müller D; Ghadimi BM; Siemer A; Markus PM; Füzesi L; Becker H
    Chirurg; 2003 Mar; 74(3):224-34. PubMed ID: 12647079
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is final TNM staging a predictor for survival in locally advanced rectal cancer after preoperative chemoradiation therapy?
    Kuo LJ; Liu MC; Jian JJ; Horng CF; Cheng TI; Chen CM; Fang WT; Chung YL
    Ann Surg Oncol; 2007 Oct; 14(10):2766-72. PubMed ID: 17551794
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CEA - a predictor for pathologic complete response after neoadjuvant therapy for rectal cancer.
    Wallin U; Rothenberger D; Lowry A; Luepker R; Mellgren A
    Dis Colon Rectum; 2013 Jul; 56(7):859-68. PubMed ID: 23739192
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term control of T2-T3 rectal adenocarcinoma with radiotherapy alone.
    Gerard JP; Chapet O; Ramaioli A; Romestaing P
    Int J Radiat Oncol Biol Phys; 2002 Sep; 54(1):142-9. PubMed ID: 12182984
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluating mesorectal lymph nodes in rectal cancer before and after neoadjuvant chemoradiation using thin-section T2-weighted magnetic resonance imaging.
    Koh DM; Chau I; Tait D; Wotherspoon A; Cunningham D; Brown G
    Int J Radiat Oncol Biol Phys; 2008 Jun; 71(2):456-61. PubMed ID: 18164860
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neoadjuvant capecitabine combined with standard radiotherapy in patients with locally advanced rectal cancer: mature results of a phase II trial.
    Dunst J; Debus J; Rudat V; Wulf J; Budach W; Hoelscher T; Reese T; Mose S; Roedel C; Zuehlke H; Hinke A
    Strahlenther Onkol; 2008 Sep; 184(9):450-6. PubMed ID: 19016023
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Can pathological complete response in the primary tumour following pre-operative pelvic chemoradiotherapy for T3-T4 rectal cancer predict for sterilisation of pelvic lymph nodes, a low risk of local recurrence and the appropriateness of local excision?
    Hughes R; Glynne-Jones R; Grainger J; Richman P; Makris A; Harrison M; Ashford R; Harrison RA; Livingstone JI; McDonald PJ; Meyrick Thomas J; Mitchell IC; Northover JM; Phillips R; Wallace M; Windsor A; Novell JR
    Int J Colorectal Dis; 2006 Jan; 21(1):11-7. PubMed ID: 15864605
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.